Novo Nordisk Looks to Liver Disease Data to Broaden GLP-1’s Reach
24.05.2026 - 05:12:19 | boerse-global.de
Novo Nordisk’s stock has clawed back some ground in recent weeks, rising 16.2% over the past 30 days, but remains 13.3% in the red for 2026 and roughly 45% below its yearly peak. With the European Association for the Study of the Liver (EASL) congress opening in Barcelona on Tuesday, investors are watching for evidence that semaglutide can do more than treat obesity and diabetes.
The Danish drugmaker will present fresh analyses from the ESSENCE phase 3 programme, which has already shown that a 2.4 mg dose of semaglutide significantly reduces liver inflammation and fibrosis in patients with MASH — the inflammatory form of metabolic fatty liver disease that can progress to cirrhosis, liver failure and cancer. An estimated 250 million people globally live with MASH, yet nine out of ten cases go undiagnosed. New data at EASL will focus on liver safety profiles and subgroup outcomes, specifically in postmenopausal women and Japanese patients — populations that have historically been underrepresented in liver disease trials. If these sub-analyses show consistent benefits, they could strengthen the commercial case for semaglutide in hepatology, an area where effective therapies have long been scarce.
Pipeline Depth Extends Beyond the Liver
Beyond the immediate catalyst in Barcelona, Novo Nordisk’s pipeline continues to develop. The company filed CagriSema — a fixed-dose combination of the long-acting amylin analogue cagrilintide (2.4 mg) and semaglutide (2.4 mg) — with the FDA in December 2025, with a decision expected by the end of 2026. The REDEFINE-11 phase 3 trial, designed to explore the full weight reduction potential of CagriSema, is due to report in the first half of 2027. A separate phase 3 study with a higher dose is slated for the second half of 2026.
Meanwhile, AMAZE-12, a phase 3 trial initiated in May 2026, is testing a dual GLP-1/amylin receptor agonist not for initial weight loss but for weight maintenance after losing weight. Earlier phase 1b/2a data showed a 22% reduction in weight over 36 weeks, while an oral phase 1 formulation yielded 13.1% after 12 weeks. Weight maintenance is a commercially underdeveloped segment that could widen Novo Nordisk’s lead over Eli Lilly if the clinical data hold up.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
At the upcoming American Diabetes Association (ADA) meeting in New Orleans, starting June 5, Novo Nordisk will hold an R&D investor event on June 7. A presentation on CagriSema will examine its effects on appetite and brain activity in overweight and obese individuals, complementing the broader strategy to secure its position beyond Wegovy.
Oral Wegovy Gains Traction
The company’s oral formulation of Wegovy is also gathering momentum. In the first quarter, it generated around 1.3 million prescriptions. Novo Nordisk plans to launch the Wegovy pill outside the US in the second half of 2026, pending regulatory approvals. This follows a strong overall quarter: revenues rose 32% on a currency-adjusted basis to 96.8 billion Danish kroner (US$15.2 billion). International obesity sales alone climbed 44% in the period.
Buyback Supports Shares, But Data Are the Driver
Behind the scenes, Novo Nordisk continues to return capital to shareholders. The current buyback programme allows for up to 15 billion Danish kroner over 12 months, with up to 11.2 billion kroner earmarked for B-shares between 6 May 2026 and 1 February 2027. Through 13 May, the company had repurchased nearly 16 million B-shares at an average price of 260.62 kroner each, for a total of about 4.17 billion kroner. It now holds 33.2 million own B-shares, representing 0.7% of total capital.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Despite this support, the stock closed at €38.74 on Friday — roughly 35% below its level a year ago and still beneath its 200-day moving average of €42.19. It has recovered to trade 11.5% above its 50-day average, but remains 8.2% below the longer-term trend line, suggesting the uptrend is not yet fully established. The company’s guidance for 2026 was raised after the first quarter, with revenue and operating profit now seen falling 4% to 12% in constant currencies, compared with an earlier forecast of a 5% to 13% decline. The next regular quarterly report is due on 5 August, followed by a Capital Markets Day on 21 September. For now, the data from Barcelona will be the first real test of whether semaglutide’s story extends beyond weight loss — and whether Novo Nordisk’s share price can build on its recent gains.
Ad
Novo Nordisk Stock: New Analysis - 24 May
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
